STANDARD BIOTOOLS INC. (LAB) research

STANDARD BIOTOOLS INC.
ShareXLinkedInReddit
Sector
Healthcare
Industry
Medical Devices
Last price
$0.75
As of

STANDARD BIOTOOLS INC. (LAB): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-05.

As of . Source: SEC EDGAR filings for LAB. Method and limitations.

SHARE THIS CARD

Share the LAB intelligence card

A branded snapshot of LAB: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion LAB intelligence card preview
Post to X
LIVE TERMINAL

See LAB live in the terminal

Track LAB's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live LAB terminal, free

Active signals for LAB

FREE, NO ACCOUNT

Every signal on LAB, as it fires

You are seeing 5 of 36 signals recorded on LAB since 2026-05-30.

The five above landed across 2 days. The other 31 were recorded on 4 other days. 26 of the 36 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in LAB (2026Q2)

Manager / securityMarket value% portfolioQoQ
VIKING GLOBAL INVESTORS LPCUSIP 34385P108 · 2026Q2$48.3M0.14%,
MILLENNIUM MANAGEMENT LLCCUSIP 34385P108 · 2026Q2$2.9M0.00%,
D. E. Shaw & Co., Inc.CUSIP 34385P108 · 2026Q2$2.3M0.00%,
CITADEL ADVISORS LLCCUSIP 34385P108 · 2026Q2$1.9M0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 34385P108 · 2026Q2$816K0.00%,
Point72 Asset Management, L.P.CUSIP 34385P108 · 2026Q2$582K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, LAB

LAB mentioned in Kresmion daily briefs

LAB against its peers

LAB's operating margin of -129.2% ranks in the 25th percentile of 21 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.

MetricLABPeer medianPercentilen
Revenue FY85.3M USD85.2M USD5221
Gross margin49.9%59.4%2620
Operating margin-129.2%-25.5%2521
Net margin-87.8%-27.7%2521
Return on equity-17.7%-47.9%6420
P / En/a24.2xn/a5

Peers (22): TLSI, TMCI, CATX, VMD, OFIX, RCEL, CV, INFU, STIM, ELMD, CLPT, MASS, NPCE, TCMD, SENS, EBRCZ, QSI, DCTH, LUCD, KIDS, OWLT, QTRX. Left out: MOBI (no annual filing), PROF (no annual filing), BWAY (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (LAB: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more LAB signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to LABand get the insider, 13F, options, and confluence read in one view.

Open the live LAB terminal, free